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cramping sensation in the lower abdomen or back during 
menstruation.[1] The reported prevalence of dysmenorrhea 
varies from 16% to 91%. There is no way to diagnose 
them as dysmenorrhea objectively. Primary dysmenorrhea 
is common among young women, and secondary 
dysmenorrhea conditions, such as endometriosis, are 
common among older women.[2] Although classified 
differently, these two types of dysmenorrhea are caused 
by the same chemical mediators.[2]
Mast cells are known to contain various mediators 
such as histamine, prostaglandin, serotonin, and 
nerve growth factor. These mediators can stimulate 
INTRODUCTION
Dysmenorrhea is a common gynecological complaint 
among reproductive age females, characterized by a painful 
Abstract
Background: Mast cells are observed in peritoneal endometriosis which causes dysmenorrhea. 
However, there is no report about the relationship between endocervical mast cells and 
dysmenorrhea. The aim of this study is to evaluate the relationship using endocervical smears. 
Materials and Methods: Between January 2016 and June 2016, patients filled out a questionnaire 
regarding dysmenorrhea and were classified into the dysmenorrhea or the control group (without 
dysmenorrhea). Patients underwent endocervical brushing and endocervical smears were obtained. 
The smears were stained with methylene blue to detect mast cells. The number of mast cells per 
slide was counted by microscopy and recorded. Results: Eighty‑nine patients were enrolled in this 
study (dysmenorrhea group, 34; control group, 55). The median number of mast cells present in the 
endocervical one slides was 35 (interquartile range, 17–58) and 2 (interquartile range, 0–6) in the 
dysmenorrhea and control groups, respectively. There was a significant difference in the number of 
mast cells between the two groups (P < 0.0001). Conclusion: More mast cells were observed in the 
endocervical smears of women with dysmenorrhea than in those of women without dysmenorrhea.
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nociceptive neurons. Furthermore, the activation 
of mast cells indirectly causes pain through the 
recruitment of neutrophils and macrophages, which 
also releases pain‑related mediators.[3] Therefore, mast 
cell activation is considered one of the mechanisms of 
dysmenorrhea.[4,5]
According to a report about mast cell distribution in 
the human uterus, there was no change in the number 
of mast cells between the proliferative and secretory 
phases of the menstrual cycle in the endometrium, 
myometrium, or cervix.[6] However, little is known about 
the relationship between dysmenorrhea and mast cells in 
the uterus. In this study, we investigated the association 
between dysmenorrhea and uterine mast cells using 
endocervical smears, which are simple and minimally 
invasive tests commonly performed in the gynecologic 
clinic.
MATERIALS AND METHODS
Patients
This study was approved by the Ethics Committee of 
Shiga University of Medical Science (approval number 
26‑217), and written informed consent was obtained 
from all the participants. The study protocol conforms 
to the provisions of the Declaration of Helsinki 
(as revised in Tokyo 2004). This study was performed 
from January 2016 to June 2016 at Shiga University 
Hospital and Tsuji Ladies clinic. Patients were excluded 
from the study if they had hormonal therapy, previous 
cervical surgery, any cervicitis and vaginitis, or an 
irregular menstrual cycle. Eligible patients completed 
a questionnaire to assess symptoms of dysmenorrhea 
and underwent a cervical smear for cancer screening 
followed by pelvic ultrasound examination. Cases of 
suspected endometrial cysts were confirmed by magnetic 
resonance imaging. All patients were classified into the 
dysmenorrhea group or the control group  (without 
dysmenorrhea).
Smears obtained using endocervical brushing
We excluded the cervical mucosa using a dry swab 
and inserted an Endo‑Cervex‑Brush®  (Rovers Medical 
Devices B.V., Oss, The Netherlands) into the cervical 
canal to collect endocervical cells. The brush was slowly 
turned four times and then smeared onto two glass 
slides gently and uniformly. One slide was screened for 
cancer. The other slide was dried and immersed in 99.9% 
methanol for 3 min. After fixation, the slide was bathed in 
Eosinostain‑Torii® (Torii Pharmaceutical Co. Ltd., Tokyo, 
Japan) for 1  min. This stain contains methylene blue, 
which stains mast cells in the same fashion as toluidine 
blue. After gentle washing, the slides were rinsed with 
methanol for 1 min and dried.
Analysis
All patient slides were evaluated using a light microscope 
(400‑fold magnification), and the number of mast 
cells was counted. The count was performed by two 
investigators blinded to the patient group assignments. 
Statistical analysis was performed with GraphPad Prism, 
version 6 (GraphPad Software, Inc., La Jolla, CA, USA). 
Because data were not normally distributed, we used 
nonparametric methods. Data were analyzed using 
the Mann–Whitney U‑test, and values are expressed 
as medians and interquartile ranges. A P  <  0.05 was 
considered statistically significant.
RESULTS
Eighty‑nine patients were enrolled in this study: 34 in the 
dysmenorrhea and 55 in the control group (mean age, 
36.1 and 39.1  years, respectively). No malignancy was 
identified in any patient. A methylene blue‑stained slide 
with mast cells is shown in Figure 1. The median number 
of mast cells per slide was 35 (17–58) in the dysmenorrhea 
group and 2 (0–6) in the control group and this difference 
was statistically significant (P < 0.0001) [Figure 2]. There 
was no significant difference in the number of mast cells 
during the menstrual cycle in each group [Table 1].
Table 1: The number of mast cells per one slide 
in each menstrual cycle
Group Menstrual cycle The number of mast 
cell
P
Median 
(interquartile range)
Dysmenorrhea Proliferative (n=14) 35 (12-68) NS
Secretory (n=20) 34.5 (20-48)
Control Proliferative (n=26) 1 (0-7) NS
Secretory (n=29) 2 (1-4)
NS: Nonsignificant difference
Figure 1: Mast cells stained by methylene blue on a glass slide observed at 
high-power (×400). Granules in mast cells are clearly observed
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DISCUSSION
We investigated the association between dysmenorrhea and 
uterine mast cells by comparing the endocervical smears 
of patients with and without dysmenorrhea. This study 
revealed that an increased number of mast cells are present 
in the endocervical smears of women with dysmenorrhea. 
Women with any cervicitis and vaginitis were excluded 
from this study because one report indicated an increased 
number of mast cells in association with vaginal 
trichomoniasis.[7] Although the association between mast 
cells in cervical smears and uterine cervix neoplasia is not 
clear, none of our patients had a smear showing dysplastic 
or malignant cells. There is a reported relationship between 
mast cells and pain in diseases other than dysmenorrhea. 
Barbara et  al.[8] documented that colonic mast cell 
infiltration and mediator release in proximity to mucosal 
innervation contribute to abdominal pain in patients 
with irritable bowel syndrome. Furthermore, mast cells 
are located in the central nervous system and modulate 
the nociceptive process; they perform a similar function 
in other regions of the body.[9] Of equal importance, the 
release of mast cell mediators such as histamine and 
serotonin in the uterine myometrium evokes strong 
contractions.[10] Furthermore, the prostaglandin which 
causes the uterus to contract is produced by activated mast 
cells.[11] Therefore, the association between increased mast 
cells in the uterine cervix and dysmenorrhea identified in 
this study is consistent with previous findings. Because no 
change was observed in the number of mast cells during 
the menstrual cycle, these cells may be activated especially 
during menstruation.
One of the limitations of this study is to be unclear the 
type of dysmenorrhea, which is primary or secondary 
dysmenorrhea. However, 11  patients had endometrial 
cyst in the dysmenorrhea group of this study. Endometrial 
cyst clearly indicated the secondary dysmenorrhea and 
endometriosis. There was no significant difference in 
the number of mast cells in the smears of dysmenorrhea 
patients with an endometrial cyst (n = 11) versus those 
without an endometrial cyst  (n  =  23). In general, the 
severity of endometriosis increases in the presence of 
an endometrial cyst according to the revised American 
Society for Reproductive Medicine classification.[12] This 
result suggested that the number of mast cells in an 
endocervical smear had no association with the severity 
of endometriosis and dysmenorrhea.
On the other hand, several reports suggest a relationship 
between mast cells and endometriosis.[13,14] An association 
between atopic disease and endometriosis has also been 
reported.[15,16] However, we could not demonstrate an 
association between allergic disease and mast cells in the cervix 
in this study. Further studies are also needed in patients with 
more precise diagnoses; i.e., radioallergosorbent‑confirmed 
allergic disease and laparoscopy‑confirmed endometriosis 
to examine the type of dysmenorrhea.
To the best of our knowledge, this study is the first to 
report a higher number of mast cells in the endocervical 
smears of patients with dysmenorrhea compared to 
those of patients without dysmenorrhea. Our findings 
are preliminary, and it is unclear whether the increased 
number of mast cells we found is the cause or result of 
dysmenorrhea. However, the evidence of increased mast 
cells in association with dysmenorrhea may contribute 
to the establishment of a novel method for the objective 
evaluation of this condition.
CONCLUSION
In this study, we performed endocervical smears and 
found that patients with dysmenorrhea had a higher 
median number of mast cells compared to patients 
without dysmenorrhea, and this difference was statistically 
significant. To the best of our knowledge, this is the first 
study to implicate mast cells in dysmenorrhea. These 
findings may contribute to the establishment of a novel 
method for the objective evaluation of this condition.
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Figure 2: Box‑and‑whisker plot comparing the number of mast cells in 
endocervical smears between patients with dysmenorrhea and controls 
without dysmenorrhea. The number of mast cells in the dysmenorrhea 
group (n = 34) was significantly higher than the number in the control 
group (n = 55) (P < 0.0001).
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